Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Patients with Follicular Lymphoma from 2012 to 2015 in Casablanca (Morocco)
American Journal of Internal Medicine
Volume 6, Issue 3, May 2018, Pages: 43-46
Received: Apr. 1, 2018; Accepted: Apr. 15, 2018; Published: May 21, 2018
Views 1383      Downloads 98
Authors
Bienvenu Houssou, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Marième Camara, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Romaric Massi, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Mohamed Rachid, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Abdellah Madani, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Meryem Qachouh, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Asma Quessar, Department of Clinical Hematology and Pediatric Oncology, Hospital August 20, Casablanca, Morocco
Article Tools
Follow on us
Abstract
Background: Follicular lymphomas are indolent lymphomas of low incidence in Africa. They are considered incurable, but recent progress has led to a significant increase in survival. The aim of our work is to describe the epidemiological, diagnostic, therapeutic and evolutionary profile of patients followed for follicular lymphoma in Casablanca, Morocco. Patients and methods: During the period of January 1, 2012 to December 31, 2015, were included, all patients diagnosed of follicular lymphoma on a histological and immunohistochemical study of the ganglion or the affected tumor tissue. The treatment was either a therapeutic abstention or chemotherapy with or without Rituximab. Results: 53 (6.4%) of the 841 patients followed-up for non-Hodgkin's lymphoma had follicular lymphoma, only 35 were included in this study. The median age of diagnosed patients was 56.1 years [27; 87] and the sex ratio 2. The primary site was the ganglion in 28 (80%) patients and 71.5% of the patients were at stage III and IV of Ann Arbor at diagnosis. According to the FLIPI score 1 about 1/3 of the patients were classified as low risk, intermediate risk and high risk, respectively. 3 (9.4%) patients were under supervision/observation, 1 patient under CVP, 13 (40.6%) patients on CHOP, 1 patient on R-chloraminophen, 14 (43.6%) on R-CHOP. In the R-CHOP group, 85.7% of the patients were on CR with a median remission of 25.8 months. 3 patients in the R-CHOP group had/received maintenance with rituximab. Discussion and conclusion: Follicular lymphoma is of low frequency and is often revealed by lymphadenopathy. The patients are diagnosed at an advanced stage. The R-CHOP protocol with rituximab maintenance is the most used and best protocol for our patients.
Keywords
Follicular Lymphoma, Frequency, Rituximab, Survival
To cite this article
Bienvenu Houssou, Marième Camara, Romaric Massi, Mohamed Rachid, Abdellah Madani, Meryem Qachouh, Asma Quessar, Epidemiological, Diagnostic, Therapeutic and Evolutionary Profile of Patients with Follicular Lymphoma from 2012 to 2015 in Casablanca (Morocco), American Journal of Internal Medicine. Vol. 6, No. 3, 2018, pp. 43-46. doi: 10.11648/j.ajim.20180603.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Fisher RI, Leblanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatement options have changed the survival of patient with follicular lymphoma. J clin Oncol 2005; 23:8447-52.
[2]
Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N, et al. Impact of rituximab and/or high dose therapy with auto transplant at time of relapse in patients with follicular lymphoma: a GELA study. J clin Oncol 2008; 26:3614-20.
[3]
Saint M, Allimani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. HEAMACARE working incidence in Europe by morphologic subtype, results oh HAEMACARE project, Blood 2010; 116: 3724-34.
[4]
Référentiels SFH. Lymphome folliculaire. Hématologie 2010; 16 (Suppl .4):35-8.
[5]
Dreyling M, Ghielmini M, Marcus R et al. ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22 (Suppl .6):vi59-63.
[6]
Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Relative frequency of non-Hodgkin lymphoma subtypes in selected centres in North Africa, the middle east and India: a review of 971 cases. Br J Haematol. 2016 Mar; 172(5):699-708.
[7]
Obafunwa JO, Akinsete I. Malignant lymphomas in Jos, Nigeria: a ten-year study. Cent Afr J Med. 1992; 38:17-25.
[8]
Shih LY, Liang DC. Non-Hodgkin’s lymphomas in Asia. Hematol Oncol Clin North Am. 1991; 5:983-1001.
[9]
Ahmad M, Khan AH, Mansoor A, Khan MA, Saeed S. Non-Hodgkin’s lymphoma—clinicopathological pattern. J Pak Med Assoc. 1992; 42: 205-207.
[10]
Calderon B, Villalon A, Augustin B, Javier B, Zamuco J, Mori S. Malignant lymphoma in Manila—a clinicopathologic study at the University of the Philippines-Philippine General Hospital Medical Center. Jpn J Clin Oncol. 1986;16:21-27.
[11]
Walter PR, Klotz F, Alfy-Gattas T, Minko-Mi-Etoua D, Nguembi-Mbina C. Malignant lymphomas in Gabon (equatorial Africa): a morphologic study of 72 cases. Hum Pathol. 1991; 22:1040-1043.
[12]
Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features: Hematolymphoreticular Study Group of the Korean Society of Pathologists: revised European-American lymphoma. Cancer. 1998;83:806-812.
[13]
Ho FC, Todd D, Loke SL, Ng RP, Khoo RK. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients: retrospective study covering an eight-year period. Int J Cancer. 1984; 34:143-148.
[14]
Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717- 720.
[15]
Herrinton LJ, Goldoft M, Schwartz SM, Weiss NS. The incidence of non-Hodgkin’s lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants. Cancer Causes Control. 1996; 7:224-230.
[16]
James J. Biagi and John F. Seymour. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002; 99:4265-4275.
[17]
Sebban C, Chassagne Clément C, Nicolas Virrelizier E, Chesquières H. Lymphome folliculaire. EMC-Hématologie: 2014; volume 9, numéro 4: 1-16.
[18]
Kane EV, Roman E, Becker N, Bernstein L, Boffetta P, Bracci PM et al. Menstrual and reproductive factors, and hormonal contraception use: association with non hodgkinien lymphoma in pooled analysis Interlymph case contrôle studies. Ann Oncol 2012; 23: 2362-74
[19]
Therapeutic results and evolution of Black African patients with follicular lymphoma: Ivory Coast experience. Koffi G, Kouakou B, Ndiaye FS, Ndathz E, Sanogo I, Sangare A. Bull Cancer. 2007 Oct; 94(10):902-6.
[20]
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579–586.
[21]
Stefano Luminari, Sara Galimberti, Annibale Versari, Irene Biasoli, Antonella Anastasia, Chiara Rusconiet al. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica 2016 Feb; 101(2): 66–68.
[22]
Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular Lymphoma International Prognostic Index. Blood 2004; 104: 1258-65.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186